CCS Medical Holdings, Inc. Sustainability Profile
CCS Medical Holdings, Inc., commonly referred to as CCS Medical, is a prominent player in the healthcare industry, headquartered in the United States. Founded in 1994, the company has established itself as a leader in providing innovative medical supplies and services, particularly in the management of chronic conditions such as diabetes and incontinence. With a strong operational presence across various regions in the US, CCS Medical offers a comprehensive range of products, including diabetes testing supplies, wound care products, and incontinence solutions. What sets CCS Medical apart is its commitment to patient-centric services, ensuring timely delivery and personalised support for individuals managing their health conditions. Recognised for its dedication to quality and customer satisfaction, CCS Medical has achieved significant milestones, positioning itself as a trusted partner in the healthcare community. The company continues to enhance its market position through strategic initiatives and a focus on improving patient outcomes.
DitchCarbon Score
How does CCS Medical Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CCS Medical Holdings, Inc.'s score of 38 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CCS Medical Holdings, Inc.'s reported carbon emissions
In 2024, CCS Medical Holdings, Inc. reported total carbon emissions of approximately 1,060,630,000 kg CO2e, comprising 1,060,630,000 kg CO2e from Scope 1 emissions and 22,130,000 kg CO2e from Scope 2 emissions. This represents a decrease from 2023, where total emissions were about 1,231,700,000 kg CO2e, with Scope 1 emissions at 1,231,700,000 kg CO2e and Scope 2 emissions at 46,950,000 kg CO2e. In 2022, the company recorded total emissions of approximately 1,336,900,000 kg CO2e, with Scope 1 emissions at 1,336,900,000 kg CO2e and Scope 2 emissions at 14,330,000 kg CO2e. CCS Medical Holdings, Inc. has not disclosed any specific reduction targets or initiatives as part of its climate commitments. The company does not report Scope 3 emissions, which typically encompass indirect emissions in the value chain. The absence of reduction targets suggests a need for further development in their climate strategy. Overall, CCS Medical Holdings, Inc. is actively monitoring its carbon footprint, with a focus on Scope 1 and Scope 2 emissions, but it currently lacks formalised reduction commitments or initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 1,336,900,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 14,330,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is CCS Medical Holdings, Inc.'s Industry?
How Carbon Intensive is CCS Medical Holdings, Inc.'s Location?
CCS Medical Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CCS Medical Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
